No Data
No Data
We Think ITeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $21
ITeos Therapeutics: Promising Phase 2 Data Boosts Buy Rating on Lead Asset Belrestotug Combination
ITeos Therapeutics Outlines Business Updates, Strategies for 2025
Express News | Iteos Therapeutics Inc - Eos-215 Ind Submission Anticipated in 1Q25
Express News | Iteos Therapeutics Inc - Eos-984 Phase 1 Monotherapy and Pd-1 Combination Data Expected in 2H25